Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Mezzanine and Stockholders??? Equity

Consolidated Statements of Mezzanine and Stockholders’ Equity - USD ($) $ in Thousands	Total	Conversion Of Convertible Preferred Stock	Series C Preferred Stock	Series D Preferred Stock	Series E Preferred Stock	AlmataBio Transaction	AlmataBio Transaction Series C Preferred Stock	Private Placement Series C Preferred Stock	Private Placement Series D Preferred Stock	Private Placement Series E Preferred Stock	Common stock	Common stock Conversion Of Convertible Preferred Stock	Common stock AlmataBio Transaction	Series C Preferred Stock Series C Preferred Stock	Additional paid-in capital	Additional paid-in capital Conversion Of Convertible Preferred Stock	Additional paid-in capital Series C Preferred Stock	Additional paid-in capital AlmataBio Transaction	Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2022	0
Balance at the beginning at Dec. 31, 2022	$ 0
Balance at the end (in shares) at Dec. 31, 2023	0			0	0
Balance at the end at Dec. 31, 2023	$ 0			$ 0	$ 0
Balance at the beginning (in shares) at Dec. 31, 2022											39,294
Balance at the beginning at Dec. 31, 2022	(10,915)										$ 0			$ 0	$ 292,909				$ (303,824)
Balance at the beginning (in shares) at Dec. 31, 2022														0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and warrants in underwritten public offering, net (in shares)											15,709
Issuance of common stock and warrants in underwritten public offering, net	13,749														13,749
Issuance of common shares pursuant to ATM Program, net (in shares)											746,076
Issuance of common shares pursuant to ATM Program, net	32,470										$ 1				32,469
Retirement of common shares in exchange for pre-funded warrants (in shares)											(5,417)
Retirement of common shares in exchange for pre-funded warrants	(3,640)														(3,874)				234
Issuance of pre-funded warrants in exchange or retirement of common shares	3,640														3,640
Exercise of pre-funded warrants for common shares (in shares)											5,850
Shares purchased through employee stock purchase plan (in shares)											99
Shares purchased through employee stock purchase plan	67														67
Impact of reverse stock split fractional share round-up (in shares)											135
Stock-based compensation	3,477														3,477
Net loss	$ (31,544)
Balance at the end (in shares) at Dec. 31, 2023	801,746										801,746
Balance at the end at Dec. 31, 2023	$ 7,304										$ 1			$ 0	342,437				(335,134)
Balance at the end (in shares) at Dec. 31, 2023			0											0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of stock (in shares)							2,412	19,946	1	1
Issuance of Series C Preferred Stock pursuant to AlmataBio Transaction							$ 11,457
Retirement of Series C Preferred Stock in exchange for issuance of common stock (in shares)	(8,648)
Retirement of Series C Preferred Stock in exchange for issuance of common stock	$ (9,799)
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity (in shares)			(13,710)
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity			$ (1,658)
Balance at the end (in shares) at Dec. 31, 2024	2			1	1
Balance at the end at Dec. 31, 2024	$ 0			$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares purchased through employee stock purchase plan (in shares)											8,301
Shares purchased through employee stock purchase plan	68														68
Impact of reverse stock split fractional share round-up (in shares)											60,779
Issuance of common stock pursuant to AlmataBio Transaction (in shares)													171,605
Issuance of common stock pursuant to AlmataBio Transaction						$ 815												$ 815
Issuance of shares pursuant to warrant exercises (in shares)											781,259	8,648,244		11,186
Issuance of shares pursuant to warrant exercises	9,647	$ 9,798	133,019								$ 1	$ 8			9,646	$ 9,790	$ 133,019
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity (in shares)														13,710
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity			$ 1,658														$ 1,658
Stock-based compensation	5,852														5,852
Net loss	$ (35,129)																		(35,129)
Balance at the end (in shares) at Dec. 31, 2024	10,471,934										10,471,934
Balance at the end at Dec. 31, 2024	$ 133,032										$ 10			$ 0	$ 503,285				$ (370,263)
Balance at the end (in shares) at Dec. 31, 2024			24,896											24,896